Deferred Tax Assets
Neurocrine Biosciences Deferred Tax Assets increased by 19.1% to $381.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 23.6%, from $499.40M to $381.40M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows relatively stable performance with a 0.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
Detailed definition
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Peer comparison
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $316.10M | $310.40M | $315.10M | $325.30M | $328.40M | $319.40M | $305.90M | $337.40M | $379.00M | $383.20M | $362.60M | $378.20M | $419.50M | $454.40M | $485.70M | $499.40M | $536.80M | $368.50M | $320.30M | $381.40M |
| QoQ Change | — | -1.8% | +1.5% | +3.2% | +1.0% | -2.7% | -4.2% | +10.3% | +12.3% | +1.1% | -5.4% | +4.3% | +10.9% | +8.3% | +6.9% | +2.8% | +7.5% | -31.4% | -13.1% | +19.1% |
| YoY Change | — | — | — | — | +3.9% | +2.9% | -2.9% | +3.7% | +15.4% | +20.0% | +18.5% | +12.1% | +10.7% | +18.6% | +33.9% | +32.0% | +28.0% | -18.9% | -34.1% | -23.6% |
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's deferred tax assets?
- Neurocrine Biosciences (NBIX) reported deferred tax assets of $381.40M in Q1 2026.
- How has Neurocrine Biosciences's deferred tax assets changed year-over-year?
- Neurocrine Biosciences's deferred tax assets decreased by 23.6% year-over-year, from $499.40M to $381.40M.
- What is the long-term trend for Neurocrine Biosciences's deferred tax assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets has grown at a 0.1% compound annual growth rate (CAGR), from $319.40M to $320.30M.
- What does deferred tax assets mean?
- Future tax savings that the company expects to realize due to past accounting differences or tax losses.